After-Hours Stock Movers 01/27: (EYPT) (AGTC) (NOW) Higher; (AMC) (AXDX) (EXPR) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
Go back to After-Hours Stock Movers 01/27: (EYPT) (AGTC) (NOW) Higher; (AMC) (AXDX) (EXPR) Lower (more...)
January 28, 2021 7:10 AM EST
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).
EYP-1901 leverages the Companys proprietary Durasert® drug delivery technology that has been used in four FDA-approved products, including EyePoints YUTIQ® for chronic non-infectious uveitis affecting the posterior segment of the eye. EYP-1901 uses a bioerodible Durasert formulation combined with a clinically validated anti-VEGF molecule, vorolanib. In oral formulation, vorolanib demonstrated efficacy and... More
January 28, 2021 6:35 AM EST
Mizuho Securities analyst Gregg Moskowitz raised the price target on ServiceNow (NYSE: NOW) to $610.00 (from $600.00) while maintaining a Buy rating.
The analyst commented, "NOW reported a very good 4Q, led by subscription billings growth of roughly 40% that easily beat consensus estimates of... More
